The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
Age 18-80 years
Diagnosis of generalized myasthenia gravis with generalized muscle weakness and fitting MGFA clinical classification II-IV
Additional inclusion criteria are defined in the protocol
History of thymic surgery within 6 months of screening
History of malignancy within the last 5 years
Additional exclusion criteria are defined in the protocol